Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia
Phase 2
Completed
- Conditions
- COVID-19 Pneumonia, Impaired Respiratory Function
- Interventions
- Drug: Standard of Care (SoC)
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 143
- Registration Number
- NCT04382053
- Locations
- ๐ช๐ธ
Novartis Investigative Site, Madrid, Spain
Study of Efficacy and Safety of MAS825 in Patients With COVID-19
Phase 2
Completed
- Conditions
- COVID-19 Pneumonia, Impaired Respiratory Function
- Interventions
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 140
- Registration Number
- NCT04382651
- Locations
- ๐บ๐ธ
Novartis Investigative Site, Mesquite, Texas, United States
Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia
Phase 3
Completed
- Conditions
- Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-04-27
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 454
- Registration Number
- NCT04362813
- Locations
- ๐ฌ๐ง
Novartis Investigative Site, London, United Kingdom
Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 432
- Registration Number
- NCT04362137
- Locations
- ๐ฌ๐ง
Novartis Investigative Site, Manchester, United Kingdom
Managed Access Programs for ABL001, Asciminib
- Conditions
- Chronic Myeloid Leukemia in Chronic Phase
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04360005
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease
Phase 3
Completed
- Conditions
- Covid-19
- Interventions
- Drug: PlaceboDrug: HCQDrug: HCQ+AZT
- First Posted Date
- 2020-04-22
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT04358081
- Locations
- ๐บ๐ธ
Novartis Investigative Site, Seattle, Washington, United States
An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 562
- Registration Number
- NCT04353492
- Locations
- ๐บ๐ธ
Fullerton Neuro and Headache Ctr, Fullerton, California, United States
๐บ๐ธCU Anschutz Med Campus, Aurora, Colorado, United States
๐บ๐ธChristiana Care Health Services, Newark, Delaware, United States
A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP
Phase 2
Completed
- Conditions
- Immune Thrombocytopenia (ITP)
- Interventions
- First Posted Date
- 2020-04-15
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT04346654
- Locations
- ๐ฉ๐ช
Novartis Investigative Site, Kronach, Germany
Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness
- Conditions
- Severe/Very Severe COVID-19 Illness
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04337359
Lamprene Multiple Patient Program
- Conditions
- Non-Tuberculous Mycobacterial (NTM) Infections
- First Posted Date
- 2020-04-03
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04334070
ยฉ Copyright 2025. All Rights Reserved by MedPath